Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: axial spondyloarthritis

FDA Update: New Drug Approvals, New & Expanded Indications, & More

Susan Bernstein  |  March 12, 2020

ATLANTA—New drug approvals, new and expanded drug indications, and important safety and other updates relevant for rheumatologists were presented by three physicians from the U.S. Food & Drug Administration (FDA) on Nov. 11 at the 2019 ACR/ARP Annual Meeting. New JAK Inhibitor Approved for RA On Aug. 16, 2019, the FDA approved upadacitinib (Rinvoq), an…

Filed under:Biologics/DMARDsDrug UpdatesMeeting Reports Tagged with:2019 ACR/ARP Annual MeetingapremilastCertolizumab PegolFebuxostatixekizumabJAK inhibitorsnintedanibrituximabU.S. Food and Drug Administration (FDA)upadacitinib

FDA Rheumatology Update: New Drug Approvals, Plus Expanded Drug Indications & Safety Concerns

Susan Bernstein  |  February 12, 2020

Last year, the FDA was busy with new biologic and other drug approvals, new and expanded drug indications, and important safety updates relevant to rheumatology…

Filed under:Drug Updates Tagged with:2019 ACR/ARP Annual MeetingBiologicsFDAU.S. Food and Drug Administration (FDA)

Ankylosing Spondylitis & Uveitis: An Ophthalmologist’s Perspective

Jason Liebowitz, MD, FACR  |  December 18, 2019

It’s often said the eyes are the window to the soul, and in the case of ankylosing spondylitis and other spondylo­arthropathies, one can also say the eyes are the window to systemic disease. Although uveitis occurs in approximately 2–5% of patients with inflammatory bowel disease, 6–9% of patients with psoriatic arthritis and 25% of patients…

Filed under:Axial SpondyloarthritisConditions Tagged with:Ankylosing SpondylitisAS Resource CenterHLA-B27opthamologistUveitis

Do Patients with Ankylosing Spondylitis in Remission Still Need TNF Inhibitors?

Lara C. Pullen, PhD  |  October 24, 2019

Patients with axial spondyloarthritis have a chronic, immune-mediated inflammatory disease that tends to localize to the sacroiliac joints and spine. Ankylosing spondylitis is, perhaps, the most representative of this group of diseases. Rheumatologists treat patients with axial spondyloarthritis with biologics, such as tumor necrosis factor inhibitors (TNFi’s), which can improve quality of life, activity and…

Filed under:Axial SpondyloarthritisConditionsResearch Rheum Tagged with:Ankylosing SpondylitisRemissionTNF inhibitors

Iguratimod May Hold Promise for Treating Autoimmune Disease

Natasha Yetman  |  October 22, 2019

NEW YORK (Reuters Health)—Iguratimod, a disease-modifying drug marketed in China and Japan, appears to be effective in treating rheumatoid arthritis (RA) and possibly other autoimmune diseases, while protecting against adverse bone effects, researchers from China say. Iguratimod is a methane sulfonanilide compound that influences several anti-inflammatory and immune-modulatory pathways and has an anabolic effect on…

Filed under:Drug Updates Tagged with:Autoimmune diseaseboneChinaiguratimod

‘Cookbook Medicine’ Is More Popular Than Ever (& That’s a Good Thing)

Paula Marchetta, MD, MBA  |  October 18, 2019

In 2004, the British Medical Journal published an article titled, “Resisting Cookbook Medicine,” which looked askance at the “routine use of pre­determined directives” in clinical practice because it reduced doctors to practicing so-called cookbook medicine and eroded the art of medicine.1 Fast forward 15 years, and we find our appetite for “predetermined directives”—what we now…

Filed under:President's Perspective Tagged with:cookbook medicineDevelopment and Evaluation (GRADE)evidence-based guidelinesGrading of RecommendationsGuidelines

Ankylosing Spondylitis & Uveitis: An Ophthalmologist’s Perspective

Jason Liebowitz, MD, FACR  |  September 26, 2019

It’s often said the eyes are the window to the soul, and in the case of ankylosing spondylitis and other spondyloarthropathies, one can also say the eyes are the window to systemic disease. Although uveitis occurs in approximately 2–5% of patients with inflammatory bowel disease, 6–9% of patients with psoriatic arthritis and 25% of patients…

Filed under:Axial SpondyloarthritisConditions Tagged with:Ankylosing SpondylitisUveitis

FDA Approves Ixekizumab for Treating Active Ankylosing Spondylitis

Michele B. Kaufman, PharmD, BCGP  |  September 23, 2019

Data from two phase 3 studies were used to support the FDA’s approval of ixekizumab for adults with ankylosing spondylitis…

Filed under:Axial SpondyloarthritisDrug Updates Tagged with:Ankylosing SpondylitisFDAixekizumabU.S. Food and Drug Administration (FDA)

No Gain with Pain: Exercise & Physical Function in Patients with Rheumatic Disease

Jason Liebowitz, MD, FACR  |  September 9, 2019

Pain can deter patients with rheumatic disease from engaging in physical activity. But the latest research shows exercise helps reduce pain, & other influences may also affect patients’ activity levels, particularly after surgery…

Filed under:Axial SpondyloarthritisConditionsEULAR/OtherMeeting ReportsOsteoarthritis and Bone DisordersRheumatoid Arthritis Tagged with:EULARExercisePainPain Managementphysical activity

These Digital Tools Aren’t Just Hype, Can Actually Help Rheumatologists

Thomas R. Collins  |  February 18, 2019

CHICAGO—Every minute, it seems, a new digital tool is introduced in medicine. Whether it’s a new digital measuring stick, a new data-crunching system or a new app, the tech tools form an endless convoy of options. But are they worth it? Will they really help you do your job better? Will they help patients feel…

Filed under:Meeting ReportsTechnology Tagged with:2018 ACR/ARHP Annual Meetingadherencepatient dataPROMISwearable device

  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 19
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences